Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension
Sponsor
Alcon Research (Industry)
Overall Status
Completed
CT.gov ID
NCT00061503
Collaborator
(none)
1
11
Study Details
Study Description
Brief Summary
The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension
Study Start Date
:
Apr 1, 2003
Actual Primary Completion Date
:
Mar 1, 2004
Actual Study Completion Date
:
Mar 1, 2004
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
-
Subjects 18 years of age or older
-
of either sex
-
of any race
-
diagnosed with ocular hypertension or open angle glaucoma
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Alcon Call Center | Call for Details | Nebraska | United States |
Sponsors and Collaborators
- Alcon Research
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00061503
Other Study ID Numbers:
- C-01-55
First Posted:
May 30, 2003
Last Update Posted:
Aug 5, 2008
Last Verified:
Aug 1, 2008
Keywords provided by ,
,
Additional relevant MeSH terms: